Resumo
Introduction: Hepatorenal syndrome (HRS) is a severe complication of liver cirrhosis and other advanced liver diseases, characterized by a rapid deterioration of renal function in patients with liver failure. This syndrome results from a complex alteration in renal hemodynamics, leading to significant cardiovascular manifestations. HRS is manifested through abnormalities in renal perfusion, which are often associated with reduced blood pressure, increased peripheral vascular resistance, and decreased cardiac output. Objective: To analyze the cardiovascular manifestations associated with hepatorenal syndrome, focusing on understanding the pathophysiological mechanisms, the effects on the cardiovascular system, and the available management strategies. Methodology: The methodology was based on the PRISMA checklist guidelines to ensure transparency and rigor in the review. Searches were conducted in the PubMed, Scielo, and Web of Science databases using descriptors such as "hepatorenal syndrome," "cardiovascular complications," "hypotension," "vascular dilation," and "acute renal failure." The selected articles were those published in the last 10 years. Inclusion criteria included: studies discussing cardiovascular manifestations of HRS, clinical studies with relevant hemodynamic data, and articles providing a detailed analysis of cardiovascular pathophysiology in HRS. Exclusion criteria included: studies outside the defined time scope, articles not directly addressing cardiovascular aspects of HRS, and publications lacking substantial empirical data. Results: The main topics identified included significant changes in cardiovascular function, such as arterial hypotension and increased systemic vascular resistance. The review revealed that HRS is frequently accompanied by reduced cardiac output and changes in circulatory system dynamics, which can exacerbate liver failure. It was also observed that treating HRS often requires specific strategies to manage cardiovascular effects, such as the use of vasoconstrictors and diuretics. Conclusion: Hepatorenal syndrome is a complex condition with significant impacts on the cardiovascular system. Cardiovascular manifestations of HRS include hemodynamic changes that exacerbate liver failure and present considerable therapeutic challenges. Understanding these aspects is crucial for developing effective treatment strategies and improving the prognosis for patients with HRS.
Referências
Ruiz del Arbol Olmos L. Síndrome hepatorrenal [Hepatorenal syndrome]. Gastroenterol Hepatol. 2002;25 Suppl 1:15-24.
Baccaro ME, Guevara M. Síndrome hepatorrenal [Hepatorenal syndrome]. Gastroenterol Hepatol. 2007;30(9):548-554. doi:10.1157/13111697
Alvo M, Vargas L. Sindrome hepatorrenal [Hepatorrenal syndrome (author's transl)]. Rev Med Chil. 1977;105(3):187-190.
Ortega R, Calahorra B, Ginès P. Vasoconstrictores en el tratamiento del síndrome hepatorrenal [Vasoconstrictors in the treatment of hepatorenal syndrome]. Nefrologia. 2002;22 Suppl 5:56-61.
Cárdenas A, Ginès P. Hiponatremia dilucional, síndrome hepatorrenal y trasplante hepático [Dilutional hyponatremia, hepatorenal syndrome and liver transplantation]. Gastroenterol Hepatol. 2008;31(1):29-36. doi:10.1157/13114568
Arroyo V. Fisiopatología de la ascitis refractaria y el síndrome hepatorrenal [Physiopathology of refractory ascites and the hepatorenal syndrome]. Nefrologia. 2002;22 Suppl 5:41-46.
Ginès P, Terra C, Torre A, Guevara M. Papel de la albúmina en el tratamiento del síndrome hepatorrenal en la cirrosis [Role of albumin in the treatment of hepatorenal syndrome in cirrhosis]. Gastroenterol Hepatol. 2005;28(2):80-84. doi:10.1157/13070706
Guevara M. Tratamiento del síndrome hepatorrenal [Treatment of hepatorenal syndrome]. Gastroenterol Hepatol. 2003;26(4):270-274. doi:10.1016/s0210-5705(03)70353-7
Terres AZ, Balbinot RS, Muscope ALF, et al. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol. 2022;45(1):25-39. doi:10.1016/j.gastrohep.2021.02.007
Torre A, Terra C, Guevara M, Ginès P. Influencia de la disfunción circulatoria en el tratamiento de la ascitis y del síndrome hepatorrenal: tratamiento vasoconstrictor y fármacos acuaréticos [Influence of circulatory dysfunction on the treatment of ascites and hepatorenal syndrome: vasoconstrictor and diuretic drug treatment]. Gastroenterol Hepatol. 2004;27 Suppl 1:8-14.
Pavão dos Santos OF, Schor N, Higa EM, Sigulem D, Ramos OL. Novos aspectos da fisiopatologia e do tratamento da síndrome hepatorrenal [New aspects of the physiopathology and treatment of the hepatorenal syndrome]. AMB Rev Assoc Med Bras. 1984;30(1-2):20-25.
López-Novoa JM. El síndrome hepatorrenal: sus relaciones con la fisiopatología de la retención renal de agua y sal en la cirrosis hepática [The hepatorenal system: its relation to the physiopathology of renal water and salt retention in liver cirrhosis]. Rev Clin Esp. 1988;183(1):1-2.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Marielly da Silva, Thaís Augusta Quirino Esteves, Thiago Mendonça Estrela Nascente, Luis Felipe Brito Beffart, Izabella Trevisan Alves, Vinicius Trevisan Alves, Rejayne Carvalho branquinho, Lívia de Oliveira Cardoso, Isabela Machado de Souza, Danillo Gondim da Silva Filho